Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

Item request has been placed! ×
Item request cannot be made. ×
  Processing Request
  • Additional Information
    • Abstract:
      Objective: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline characteristics. Research design and methods: FIELD is a double-blind, placebo-controlled trial in 63 centres in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering therapy on randomization, but could start these or other drugs at any time after randomization. Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred. Results: About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%. Despite this, half of the cohort were obese (BMI > 30), most were men, two-thirds were aged over 60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome independent of their diabetes, including low HDL (60%), high blood pressure measurement or treatment for hypertension (84%), high waist measurement (68%), and raised triglycerides (52%). After a 6-week run-in period before randomisation with all participants receiving 200 mg comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides (26%) and an increase in HDL cholesterol (6.5%). Conclusion: The study will show the effect of PPAR-alpha agonist action on CHD and other vascular outcomes in patients with type 2 diabetes including substantial numbers with low to moderate CVD risk but with the various components of the metabolic syndrome. The main results of the study will be reported in late 2005. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Cardiovascular Diabetology is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • ISSN:
      1475-2840
    • Accession Number:
      10.1186/1475-2840-4-13
    • Accession Number:
      28682780
  • Citations
    • ABNT:
      Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovascular Diabetology, [s. l.], v. 4, p. 13–9, 2005. Disponível em: . Acesso em: 12 nov. 2019.
    • AMA:
      Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovascular Diabetology. 2005;4:13-19. doi:10.1186/1475-2840-4-13.
    • APA:
      Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. (2005). Cardiovascular Diabetology, 4, 13–9. https://doi.org/10.1186/1475-2840-4-13
    • Chicago/Turabian: Author-Date:
      “Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Baseline Characteristics and Short-Term Effects of Fenofibrate [ISRCTN64783481].” 2005. Cardiovascular Diabetology 4 (January): 13–19. doi:10.1186/1475-2840-4-13.
    • Harvard:
      ‘Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]’ (2005) Cardiovascular Diabetology, 4, pp. 13–9. doi: 10.1186/1475-2840-4-13.
    • Harvard: Australian:
      ‘Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]’ 2005, Cardiovascular Diabetology, vol. 4, pp. 13–9, viewed 12 November 2019, .
    • MLA:
      “Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Baseline Characteristics and Short-Term Effects of Fenofibrate [ISRCTN64783481].” Cardiovascular Diabetology, vol. 4, Jan. 2005, pp. 13–9. EBSCOhost, doi:10.1186/1475-2840-4-13.
    • Chicago/Turabian: Humanities:
      “Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Baseline Characteristics and Short-Term Effects of Fenofibrate [ISRCTN64783481].” Cardiovascular Diabetology 4 (January 2005): 13–19. doi:10.1186/1475-2840-4-13.
    • Vancouver/ICMJE:
      Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovascular Diabetology [Internet]. 2005 Jan [cited 2019 Nov 12];4:13–9. Available from: http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=a9h&AN=28682780&authtype=sso&custid=s5834912